Who is the CEO of Neuphoria Therapeutics Inc.?

The CEO of Neuphoria Therapeutics Inc. is Spyridon Papapetropoulos.

What industry does Neuphoria Therapeutics Inc. belong to?

Neuphoria Therapeutics Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector.

Where is Neuphoria Therapeutics Inc. headquartered?

Neuphoria Therapeutics Inc. is headquartered at 100 Summit Dr, Burlington, US.

What is the IPO date of Neuphoria Therapeutics Inc.?

Neuphoria Therapeutics Inc. went public on December 16, 2021.

How many employees does Neuphoria Therapeutics Inc. have?

Neuphoria Therapeutics Inc. has approximately 8 full-time employees.

Neuphoria Therapeutics Inc.

NEUP•NASDAQ

Healthcare

Medical - Pharmaceuticals

$8.50

$0.10(1.19%)

Neuphoria Therapeutics Inc. (NEUP) Company Profile & Overview

Explore Neuphoria Therapeutics Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Neuphoria Therapeutics Inc. (NEUP) Company Profile & Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

SectorHealthcare

IndustryMedical - Pharmaceuticals

CEOSpyridon Papapetropoulos

Contact Information

http://www.neuphoriatx.com

100 Summit Dr, Burlington

Company Facts

8 Employees

IPO DateDec 16, 2021

CountryUS

Actively Trading

Frequently Asked Questions

;